Last reviewed · How we verify
Arvigol (CLOBENOSIDE)
Arvigol (generic name: CLOBENOSIDE) is a drug. It is currently in Phase 2 development.
Arvigol is thought to work by inhibiting the activity of certain enzymes or proteins, although the exact mechanism is not well understood.
Arvigol, also known as CLOBENOSIDE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Arvigol's safety profile and potential side effects are not well-documented. Further research is needed to understand its mechanism of action and potential therapeutic applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLOBENOSIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a special messenger system that helps them communicate with each other. Arvigol may block or slow down this messenger system, which can affect how cells behave and respond to signals. This can potentially lead to changes in various bodily functions, but more research is needed to understand how it works and what effects it may have on the body.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arvigol CI brief — competitive landscape report
- Arvigol updates RSS · CI watch RSS
Frequently asked questions about Arvigol
What is Arvigol?
How does Arvigol work?
What is the generic name of Arvigol?
What development phase is Arvigol in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing